Evaluation of recombinant DNA-directed E.coli produced α1-antitrypsin as an anti-neutrophil elastase for potential use as replacement therapy of α1-antitrypsin deficiency

Sherwin D. Straus, Gerald A. Fells, Mark D. Wewers, Michael Courtney, Luc henri Tessier, Paul Tolstoshev, Jean Pierre Lecocq, Ronald Crystal

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

α1-antitrypsin (α1AT) deficiency is an inherited disorder almost always associated with the development of panacinar emphysema in the fourth to fifth decades. One source of α1AT for chronic replacement therapy of such individuals is that produced by E.coli directed by a cDNA coding for the human α1AT molecule. Using TG1(E.coli), an α1AT molecule produced by E.coli transformed with the plasmid-expressing vector pTG922, the present study shows that recombinant DNA-directed E.coli-produced α1AT is as an effective inhibitor of neutrophil elastase as α1AT purified from plasma. Importantly, TG1(E.coli) inhibited human neutrophil elastase with an association rate constant of 1.3±0.4×107 M-1 sec-1, similar to that of normal plasma α1AT (1.1±0.1, p>0.2). Furthermore, when TG1(E.coli) was added to α1AT-deficient plasma obtained from homozygous α1AT type Z individuals, the TG1(E.coli) remained functional and augmented the anti-neutrophil elastase activity of the serum proportional to the amount of TG1(E.coli) added. These observations suggest that if sufficient amounts of recombinant DNA methodology-produced α1AT molecules could be safely delivered to the alveolar structures of α1AT-deficient individuals, they would function to protect the alveolar walls from elastolytic attack.

Original languageEnglish
Pages (from-to)1177-1184
Number of pages8
JournalBiochemical and Biophysical Research Communications
Volume130
Issue number3
DOIs
Publication statusPublished - 15 Aug 1985
Externally publishedYes

Fingerprint

Leukocyte Elastase
Recombinant DNA
Escherichia coli
Therapeutics
Plasmas
Molecules
Secretory Proteinase Inhibitory Proteins
Pulmonary Emphysema
Rate constants
Plasmids
Complementary DNA
Association reactions
Serum

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Evaluation of recombinant DNA-directed E.coli produced α1-antitrypsin as an anti-neutrophil elastase for potential use as replacement therapy of α1-antitrypsin deficiency. / Straus, Sherwin D.; Fells, Gerald A.; Wewers, Mark D.; Courtney, Michael; Tessier, Luc henri; Tolstoshev, Paul; Lecocq, Jean Pierre; Crystal, Ronald.

In: Biochemical and Biophysical Research Communications, Vol. 130, No. 3, 15.08.1985, p. 1177-1184.

Research output: Contribution to journalArticle

Straus, Sherwin D. ; Fells, Gerald A. ; Wewers, Mark D. ; Courtney, Michael ; Tessier, Luc henri ; Tolstoshev, Paul ; Lecocq, Jean Pierre ; Crystal, Ronald. / Evaluation of recombinant DNA-directed E.coli produced α1-antitrypsin as an anti-neutrophil elastase for potential use as replacement therapy of α1-antitrypsin deficiency. In: Biochemical and Biophysical Research Communications. 1985 ; Vol. 130, No. 3. pp. 1177-1184.
@article{db74a4680a4142cf8e9fa87baed33ba5,
title = "Evaluation of recombinant DNA-directed E.coli produced α1-antitrypsin as an anti-neutrophil elastase for potential use as replacement therapy of α1-antitrypsin deficiency",
abstract = "α1-antitrypsin (α1AT) deficiency is an inherited disorder almost always associated with the development of panacinar emphysema in the fourth to fifth decades. One source of α1AT for chronic replacement therapy of such individuals is that produced by E.coli directed by a cDNA coding for the human α1AT molecule. Using TG1(E.coli), an α1AT molecule produced by E.coli transformed with the plasmid-expressing vector pTG922, the present study shows that recombinant DNA-directed E.coli-produced α1AT is as an effective inhibitor of neutrophil elastase as α1AT purified from plasma. Importantly, TG1(E.coli) inhibited human neutrophil elastase with an association rate constant of 1.3±0.4×107 M-1 sec-1, similar to that of normal plasma α1AT (1.1±0.1, p>0.2). Furthermore, when TG1(E.coli) was added to α1AT-deficient plasma obtained from homozygous α1AT type Z individuals, the TG1(E.coli) remained functional and augmented the anti-neutrophil elastase activity of the serum proportional to the amount of TG1(E.coli) added. These observations suggest that if sufficient amounts of recombinant DNA methodology-produced α1AT molecules could be safely delivered to the alveolar structures of α1AT-deficient individuals, they would function to protect the alveolar walls from elastolytic attack.",
author = "Straus, {Sherwin D.} and Fells, {Gerald A.} and Wewers, {Mark D.} and Michael Courtney and Tessier, {Luc henri} and Paul Tolstoshev and Lecocq, {Jean Pierre} and Ronald Crystal",
year = "1985",
month = "8",
day = "15",
doi = "10.1016/0006-291X(85)91739-5",
language = "English",
volume = "130",
pages = "1177--1184",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Evaluation of recombinant DNA-directed E.coli produced α1-antitrypsin as an anti-neutrophil elastase for potential use as replacement therapy of α1-antitrypsin deficiency

AU - Straus, Sherwin D.

AU - Fells, Gerald A.

AU - Wewers, Mark D.

AU - Courtney, Michael

AU - Tessier, Luc henri

AU - Tolstoshev, Paul

AU - Lecocq, Jean Pierre

AU - Crystal, Ronald

PY - 1985/8/15

Y1 - 1985/8/15

N2 - α1-antitrypsin (α1AT) deficiency is an inherited disorder almost always associated with the development of panacinar emphysema in the fourth to fifth decades. One source of α1AT for chronic replacement therapy of such individuals is that produced by E.coli directed by a cDNA coding for the human α1AT molecule. Using TG1(E.coli), an α1AT molecule produced by E.coli transformed with the plasmid-expressing vector pTG922, the present study shows that recombinant DNA-directed E.coli-produced α1AT is as an effective inhibitor of neutrophil elastase as α1AT purified from plasma. Importantly, TG1(E.coli) inhibited human neutrophil elastase with an association rate constant of 1.3±0.4×107 M-1 sec-1, similar to that of normal plasma α1AT (1.1±0.1, p>0.2). Furthermore, when TG1(E.coli) was added to α1AT-deficient plasma obtained from homozygous α1AT type Z individuals, the TG1(E.coli) remained functional and augmented the anti-neutrophil elastase activity of the serum proportional to the amount of TG1(E.coli) added. These observations suggest that if sufficient amounts of recombinant DNA methodology-produced α1AT molecules could be safely delivered to the alveolar structures of α1AT-deficient individuals, they would function to protect the alveolar walls from elastolytic attack.

AB - α1-antitrypsin (α1AT) deficiency is an inherited disorder almost always associated with the development of panacinar emphysema in the fourth to fifth decades. One source of α1AT for chronic replacement therapy of such individuals is that produced by E.coli directed by a cDNA coding for the human α1AT molecule. Using TG1(E.coli), an α1AT molecule produced by E.coli transformed with the plasmid-expressing vector pTG922, the present study shows that recombinant DNA-directed E.coli-produced α1AT is as an effective inhibitor of neutrophil elastase as α1AT purified from plasma. Importantly, TG1(E.coli) inhibited human neutrophil elastase with an association rate constant of 1.3±0.4×107 M-1 sec-1, similar to that of normal plasma α1AT (1.1±0.1, p>0.2). Furthermore, when TG1(E.coli) was added to α1AT-deficient plasma obtained from homozygous α1AT type Z individuals, the TG1(E.coli) remained functional and augmented the anti-neutrophil elastase activity of the serum proportional to the amount of TG1(E.coli) added. These observations suggest that if sufficient amounts of recombinant DNA methodology-produced α1AT molecules could be safely delivered to the alveolar structures of α1AT-deficient individuals, they would function to protect the alveolar walls from elastolytic attack.

UR - http://www.scopus.com/inward/record.url?scp=0022187010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022187010&partnerID=8YFLogxK

U2 - 10.1016/0006-291X(85)91739-5

DO - 10.1016/0006-291X(85)91739-5

M3 - Article

C2 - 3896239

AN - SCOPUS:0022187010

VL - 130

SP - 1177

EP - 1184

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -